214,897 Shares in Achieve Life Sciences, Inc. $ACHV Bought by 683 Capital Management LLC

683 Capital Management LLC acquired a new position in Achieve Life Sciences, Inc. (NASDAQ:ACHV) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 214,897 shares of the biopharmaceutical company’s stock, valued at approximately $1,068,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Franklin Resources Inc. raised its position in shares of Achieve Life Sciences by 18,747.4% in the fourth quarter. Franklin Resources Inc. now owns 4,369,193 shares of the biopharmaceutical company’s stock worth $21,715,000 after buying an additional 4,346,011 shares in the last quarter. Vanguard Group Inc. raised its position in Achieve Life Sciences by 14.5% during the third quarter. Vanguard Group Inc. now owns 2,461,802 shares of the biopharmaceutical company’s stock valued at $7,755,000 after purchasing an additional 311,925 shares in the last quarter. Hudson Bay Capital Management LP purchased a new stake in Achieve Life Sciences during the second quarter valued at about $2,652,000. Marshall Wace LLP raised its position in Achieve Life Sciences by 31.5% during the fourth quarter. Marshall Wace LLP now owns 1,019,281 shares of the biopharmaceutical company’s stock valued at $5,066,000 after purchasing an additional 244,428 shares in the last quarter. Finally, LPL Financial LLC raised its position in Achieve Life Sciences by 91.1% during the fourth quarter. LPL Financial LLC now owns 633,148 shares of the biopharmaceutical company’s stock valued at $3,147,000 after purchasing an additional 301,850 shares in the last quarter. Hedge funds and other institutional investors own 33.52% of the company’s stock.

Achieve Life Sciences Stock Down 3.4%

Shares of NASDAQ:ACHV opened at $5.36 on Thursday. The stock’s 50-day moving average price is $4.74 and its 200-day moving average price is $4.55. Achieve Life Sciences, Inc. has a 12-month low of $2.00 and a 12-month high of $6.16. The stock has a market capitalization of $550.25 million, a P/E ratio of -4.79 and a beta of 2.27. The company has a current ratio of 2.62, a quick ratio of 2.62 and a debt-to-equity ratio of 0.87.

Achieve Life Sciences (NASDAQ:ACHV) last announced its quarterly earnings data on Tuesday, May 12th. The biopharmaceutical company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.11. On average, equities analysts anticipate that Achieve Life Sciences, Inc. will post -0.91 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have weighed in on ACHV. Weiss Ratings upgraded Achieve Life Sciences from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 22nd. Canaccord Genuity Group set a $13.00 price target on Achieve Life Sciences and gave the company a “buy” rating in a research report on Monday, April 20th. HC Wainwright restated a “buy” rating and set a $12.00 price target on shares of Achieve Life Sciences in a research report on Thursday, April 16th. Finally, Wall Street Zen upgraded Achieve Life Sciences from a “sell” rating to a “hold” rating in a research report on Sunday, May 17th. Two analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $14.67.

Achieve Life Sciences Profile

Achieve Life Sciences, Inc (NASDAQ: ACHV) is a clinical-stage biotechnology company dedicated to the development and commercialization of cytisinicline, a plant-derived alkaloid for smoking cessation. The company’s mission is to offer a novel, evidence-based therapy that addresses the global need for effective and well-tolerated smoking cessation options. Achieve focuses its efforts on advancing the clinical profile of cytisinicline through rigorous development programs and regulatory engagement.

Cytisinicline (formerly marketed as Tabex® in Europe) acts as a nicotinic acetylcholine receptor partial agonist, helping reduce withdrawal symptoms and nicotine cravings.